This is a phase II study to determine the efficacy and safety of Pebolizumab when given in
combination with lenvatinib as treatment for patients with the advanced kidney cancer .
Further evaluate whether the treatment plan is beneficial to the patient's operation.Patients
will receive treatment with tislelizumab in combination with lenvatinib every 3 weeks for 3
treatment cycles in the preoperative and patients need to continue taking the drug for a year
after surgery